4.4 Article

Medications for Weight Reduction

Journal

MEDICAL CLINICS OF NORTH AMERICA
Volume 95, Issue 5, Pages 989-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mcna.2011.06.009

Keywords

Sympathomimetic drugs; Lipase inhibitor; Cannabinoid receptor antagonists; Glucagon-like peptide analogues

Funding

  1. Merck

Ask authors/readers for more resources

Only two drugs are currently approved for long-term use in the treatment of obesity, and four others for short-term use. Evaluating the risk-benefit profile is an essential first step. For individuals who have a low body mass index for whom the risk is small, the risk profile must make the drug acceptable for almost everyone. For higher-risk patients, such as those planning intestinal bypass or who have sleep apnea, a wider range of drugs may be considered. Obesity is a chronic disease that has many causes. Treatment is aimed at palliation that is, producing and maintaining weight loss. Regardless of the primary site of action, the net effect must be a reduction in food intake or increase in energy expenditure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available